#ZIIHERA #Ireland #Dublin #Jazz Pharmaceuticals #zanidatamab-hrii

Investor Webcast Announcement from Jazz Pharmaceuticals

On December 4, 2024, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) made a significant announcement regarding its upcoming investor webcast scheduled for December 11, 2024. This event will commence at 4:30 PM ET, providing an in-depth overview of its innovative drug, Ziihera® (zanidatamab-hrii), which marks a transformative approach in the treatment of biliary tract cancer (BTC).

Overview of Ziihera®

Ziihera® is a pioneering dual HER2-targeted bispecific antibody, having received accelerated approval from the U.S. Food and Drug Administration (FDA) on November 20, 2024. It is specially indicated for adults who have previously undergone treatment for unresectable or metastatic HER2-positive biliary tract cancer, as identified by FDA-approved testing. This is a landmark achievement for Jazz Pharmaceuticals in advancing treatment options for this challenging condition.

During the webcast, Jazz's senior management will outline the commercial launch plans for Ziihera®, alongside a comprehensive summary of clinical data highlighting the efficacy and necessity of this new therapeutic option. Additionally, Dr. Shubham Pant, a prominent figure in gastrointestinal medical oncology from The University of Texas MD Anderson Cancer Center, will present findings from the HERIZON-BTC-01 trial, showcasing the promising data that led to Ziihera’s FDA approval.

Importance of the Webcast

This webcast serves as a crucial platform for investors and stakeholders interested in understanding both the clinical and commercial landscapes surrounding Ziihera®. Participants can expect to gain insights into the clinical outcomes of the HERIZON-BTC-01 trial, helping to contextualize the significance of Ziihera® in addressing patient needs in the biliary tract cancer space. The connection to the larger oncological community during this presentation underscores Jazz Pharmaceuticals' commitment to delivering life-changing medicines to patients.

For those interested in attending the live session, registration is recommended at least 15 minutes prior to the broadcast to ensure a smooth connection. The company has made arrangements for live audio through their official website, and a replay will be accessible shortly after the conclusion of the event.

Safety Information

While Ziihera® brings hope to many, it is also essential to discuss the associated risks. An important safety alert regarding Ziihera® includes embryo-fetal toxicity; exposure during pregnancy can lead to significant harm. Consequently, healthcare providers and potential patients must be informed about contraceptive measures during and after treatment. Additionally, monitoring for left ventricular dysfunction is critical, with the drug indicated to cause adverse effects in some patients.

Jazz Pharmaceuticals continues to emphasize patient safety while pursuing innovation. Through Ziihera®, they aim to not only improve survival rates in biliary tract cancer patients but to also elevate the standard of care in this high-need area of oncology.

Jazz Pharmaceuticals, headquartered in Dublin, plays a vital role in the global biopharma landscape. Their dedication to developing treatments that enhance patients' quality of life is evident in their diverse portfolio, which encompasses therapies across various serious diseases, notably sleep disorders and epilepsy, alongside their growing oncology offerings.

For additional details surrounding the conference call and ongoing development of Ziihera®, interested parties can access specific information through Jazz Pharmaceuticals’ investor relations page, and stay updated on any future developments in this area.

Jazz Pharmaceuticals welcomes all interested investors and media representatives to join them as they explore the future of biliary tract cancer treatment.